INBX — Inhibrx Biosciences Share Price
0.000.00%
Last trade - 00:00- $674.94m
- $630.66m
- $1.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 68.58 | ||
| Price to Tang. Book | 68.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 444.96 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -115.03% | ||
| Return on Equity | -2031.05% | ||
| Operating Margin | -13980.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13.21 | 12.89 | 7.23 | 2.19 | 1.8 | n/a | 2 | -26.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Directors
- Mark Lappe CHM (48)
- Brendan Eckelman CFD (42)
- Kelly Deck CFO (41)
- David Matly OTH
- Klaus Wagner OTH (49)
- Douglas Forsyth IND (52)
- Jon Kayyem IND (57)
- Kimberly Manhard IND (61)
- Kristiina Vuori IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 8th, 2024
- Public Since
- May 28th, 2024
- No. of Shareholders
- 14
- No. of Employees
- 166
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 52,401,941
- Address
- 11025 N. Torrey Pines Road, Suite 140, LA JOLLA, 92037
- Web
- https://inhibrx.com/
- Phone
- +1 8587954220
- Auditors
- BDO USA, P.C.
Upcoming Events for INBX
Q3 2024 Inhibrx Inc Earnings Release
Similar to INBX
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the Inhibrx Biosciences share price?
As of Today at 15:21 UTC, shares in Inhibrx Biosciences are trading at $15.14. This share price information is delayed by 15 minutes.
How has the Inhibrx Biosciences share price performed this year?
Shares in Inhibrx Biosciences last closed at $15.14 and the price had moved by over the past 365 days. In terms of relative price strength the Inhibrx Biosciences share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Inhibrx Biosciences?
The overall consensus recommendation for Inhibrx Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Inhibrx Biosciences dividend yield?
Inhibrx Biosciences does not currently pay a dividend.
Does Inhibrx Biosciences pay a dividend?
Inhibrx Biosciences does not currently pay a dividend.
When does Inhibrx Biosciences next pay dividends?
Inhibrx Biosciences does not currently pay a dividend.
How do I buy Inhibrx Biosciences shares?
To buy shares in Inhibrx Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inhibrx Biosciences?
As of the previous close price of $15.14, shares in Inhibrx Biosciences had a market capitalisation of $793.37m.
Where are Inhibrx Biosciences shares listed?
Here are the trading details for Inhibrx Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: INBX
What kind of share is Inhibrx Biosciences?
Based on an overall assessment of its quality, value and momentum Inhibrx Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inhibrx Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Inhibrx Biosciences is $35.50. That is 134.48% above the last closing price of $15.14.
Analysts covering Inhibrx Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$5.87 for the next financial year.
What is the trend in the Inhibrx Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inhibrx Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +39.05%.
As of the last closing price of $15.14, shares in Inhibrx Biosciences were trading -5.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inhibrx Biosciences PE Ratio?
The Inhibrx Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inhibrx Biosciences?
Inhibrx Biosciences' management team is headed by:
- Mark Lappe - CHM
- Brendan Eckelman - CFD
- Kelly Deck - CFO
- David Matly - OTH
- Klaus Wagner - OTH
- Douglas Forsyth - IND
- Jon Kayyem - IND
- Kimberly Manhard - IND
- Kristiina Vuori - IND